Telemedicine in oncology: Impact on clinical outcomes, access to care, and future oncology practice.

e13539 Background: The COVID-19 pandemic accelerated the adoption of telemedicine in oncology to maintain continuity of care while minimizing infection risk. Although in-person care has largely resumed, tele oncology remains embedded in routine practice. Ongoing evaluation is needed to understand its impact on clinical outcomes, healthcare utilization, patient experience, and health equity in the post–COVID-19 era. Methods: We conducted a narrative review of published literature evaluating telemedicine across the cancer care continuum, including diagnosis, active treatment, survivorship, and palliative care. Outcomes of interest included treatment adherence, symptom control, healthcare utilization, patient and provider satisfaction, and equity considerations. Results: Evidence suggests that telemedicine is comparable to in-person care for selected oncology visits, particularly follow-up encounters, symptom management, oral therapy monitoring, survivorship care, and palliative services. Tele oncology is ass